Osteoarthritis injection may affect metabolism in diabetes

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Intra-articular corticosteroid injection (IACI) of betamethasone (eg, Celestone Soluspan) for knee osteoarthritis increases blood glucose, insulin, and insulin resistance in patients with type 2 diabetes (T2D).

Why this matters

  • Clinicians prescribing IACI should be aware of and monitor its effects on metabolism in patients with T2D.

Key results

  • Blood glucose (P=.004), insulin (P=.004), and insulin resistance (P=.003) were significantly higher than baseline at 1 day after IACI, and all returned to normal levels by day 8.
  • Control patients did not show significant changes in blood glucose, insulin, or insulin resistance between baseline, day 1, and day 8.
  • There were no significant differences in demographics between the control group and the treatment group.

Study design

  • 10 patients with noninsulin-treated T2D and painful osteoarthritis were given IACI of 1 mL of depot betamethasone.
  • Researchers measured fasting blood glucose and fasting blood insulin levels just before IACI and at 1 and 8 days after, and compared with age- and sex-matched control patients with T2D.
  • Funding: None disclosed.

Limitations

  • Small sample size.